The U.S. Food and Drug Administration today approved a risk evaluation and mitigation strategy for extended-release and long-acting opioids. Several recommendations are outlined in an FDA Blueprint for Prescriber Education that support national efforts to address the prescription drug abuse epidemic. ASAM is preparing to respond as a member of the Collaborative for REMS Education (CO*RE).
Click here to learn about the FDA Guidelines.
Click here to learn about the CO*RE Collaborative.